You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients
|
|---|---|
| Published in |
Science Translational Medicine, June 2015
|
| DOI | 10.1126/scitranslmed.aaa9301 |
| Pubmed ID | |
| Authors |
Helen Benham, Hendrik J Nel, Soi Cheng Law, Ahmed M Mehdi, Shayna Street, Nishta Ramnoruth, Helen Pahau, Bernett T Lee, Jennifer Ng, Marion E G Brunck, Claire Hyde, Leendert A Trouw, Nadine L Dudek, Anthony W Purcell, Brendan J O'Sullivan, John E Connolly, Sanjoy K Paul, Kim-Anh Lê Cao, Ranjeny Thomas |
| Abstract |
In animals, immunomodulatory dendritic cells (DCs) exposed to autoantigen can suppress experimental arthritis in an antigen-specific manner. In rheumatoid arthritis (RA), disease-specific anti-citrullinated peptide autoantibodies (ACPA or anti-CCP) are found in the serum of about 70% of RA patients and are strongly associated with HLA-DRB1 risk alleles. This study aimed to explore the safety and biological and clinical effects of autologous DCs modified with a nuclear factor κB (NF-κB) inhibitor exposed to four citrullinated peptide antigens, designated "Rheumavax," in a single-center, open-labeled, first-in-human phase 1 trial. Rheumavax was administered once intradermally at two progressive dose levels to 18 human leukocyte antigen (HLA) risk genotype-positive RA patients with citrullinated peptide-specific autoimmunity. Sixteen RA patients served as controls. Rheumavax was well tolerated: adverse events were grade 1 (of 4) severity. At 1 month after treatment, we observed a reduction in effector T cells and an increased ratio of regulatory to effector T cells; a reduction in serum interleukin-15 (IL-15), IL-29, CX3CL1, and CXCL11; and reduced T cell IL-6 responses to vimentin447-455-Cit450 relative to controls. Rheumavax did not induce disease flares in patients recruited with minimal disease activity, and DAS28 decreased within 1 month in Rheumavax-treated patients with active disease. This exploratory study demonstrates safety and biological activity of a single intradermal injection of autologous modified DCs exposed to citrullinated peptides, and provides rationale for further studies to assess clinical efficacy and antigen-specific effects of autoantigen immunomodulatory therapy in RA. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 29% |
| Australia | 4 | 19% |
| United Kingdom | 3 | 14% |
| France | 2 | 10% |
| Malaysia | 1 | 5% |
| Germany | 1 | 5% |
| Canada | 1 | 5% |
| Unknown | 3 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 62% |
| Scientists | 4 | 19% |
| Practitioners (doctors, other healthcare professionals) | 2 | 10% |
| Science communicators (journalists, bloggers, editors) | 2 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 272 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Hungary | 1 | <1% |
| China | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 268 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 52 | 19% |
| Researcher | 51 | 19% |
| Student > Bachelor | 42 | 15% |
| Student > Master | 29 | 11% |
| Other | 15 | 6% |
| Other | 37 | 14% |
| Unknown | 46 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 62 | 23% |
| Agricultural and Biological Sciences | 51 | 19% |
| Medicine and Dentistry | 48 | 18% |
| Biochemistry, Genetics and Molecular Biology | 28 | 10% |
| Chemistry | 11 | 4% |
| Other | 22 | 8% |
| Unknown | 50 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 82. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2022.
All research outputs
#514,515
of 25,315,460 outputs
Outputs from Science Translational Medicine
#1,363
of 5,415 outputs
Outputs of similar age
#5,702
of 273,446 outputs
Outputs of similar age from Science Translational Medicine
#25
of 137 outputs
Altmetric has tracked 25,315,460 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,415 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 86.5. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,446 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.